Internal Medicine · 2012 · 26 citations · 9 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyOncology PharmacotherapyHepatotoxicity ManagementLung CancerMalignant NeoplasmsToxicity ManagementTyrosine Kinase InhibitorsEgfr InhibitionErlotinib TherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentTyrosine Kinase InhibitionTyrosine Kinase Inhibitor HepatotoxicityTyrosine Kinase Inhibitor TherapyTyrosine Kinase Receptors
Gefitinib and erlotinib are first-generation small molecular inhibitors of EGFR tyrosine kinase activity. To the best of our knowledge, to date, two reports have stated that patients with NSCLC who develop severe hepatotoxicity secondary to gefitinib treatment can be safely switched to erlotinib. However, the reverse situation has not been reported. Here, we present the first case with non-small cell lung cancer harboring EGFR mutation who developed grade 3/4 hepatotoxicity after initiation of erlotinib, which resolved when therapy was changed to gefitinib. As far as we know, this is the first report showing the efficacy of gefitinib for a non-small cell lung cancer patient who developed severe hepatotoxicity while under erlotinib therapy.
9
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi et al. · New England Journal of Medicine · 2010 · 5.6K citations
Medicine, Oncology, Pharmacology +13
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rafael Rosell, Teresa Morán, Cristina Queralt et al. · New England Journal of Medicine · 2009 · 2.4K citations · Full text
Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes
Jing Li, Ming Zhao, Ping He et al. · Clinical Cancer Research · 2007 · 306 citations